Tag Archives: cardiometabolic disorders

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Ventus Launches With $60M to Shine Light on Innate Immune System Drugs

The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in many diseases. The problem, says Ventus Therapeutics CEO Marcelo Bigal, is that drug developers have been working in the dark. Scientists don’t know the […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ventus Launches With $60M to Shine Light on Innate Immune System Drugs

Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran

Seven years ago Alnylam Pharmaceuticals sold rights to one of its preclinical drugs, gaining upfront cash and $180 million in potential milestone payments, plus royalties, for a therapy taking a novel approach to lowering cholesterol. On Monday, the company announced the sale of half of the royalties it’s owed to private equity firm Blackstone for […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, Europe top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran

AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics

After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs. According to deal terms announced Wednesday, AstraZeneca (NYSE: AZN) will pay London-based Silence (LON: SLN) […]

Posted in Boston blog main, Boston top stories, Europe, Europe blog main, Europe top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics

Rhythm Pharma IPO Pops to the Tune of a $120M Upsized Offering

Rhythm Pharmaceuticals is in step with other life science companies going public, raising $120 million in its own upsized IPO. The Boston company priced its stock offering late Wednesday at $17, topping the $14 to $16 per share range it had previously set. Rhythm sold just over 7 million shares, nearly 400,000 more shares that […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on Rhythm Pharma IPO Pops to the Tune of a $120M Upsized Offering

Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within

Biotechs keep cashing in. The latest is Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY), which is entering the most critical juncture in its 13-year history as it tries to enter the rarified realm of biotechs with their own products on the market. The RNA interference firm said Monday it would tap the public markets for a […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within